Regeneron Pharmaceuticals reported a net income of $174 million, or $1.62 per basic share, in the fourth quarter of 2017 compared with a net income of $253 million, or $2.41 per basic share, in the fourth quarter of 2016.
For the full year, the company reported a net income of $1.199 billion, or $11.27 per basic share, compared with a net income of $896 million, or $8.55 per basic share, in 2016, according to a press release.
Fourth quarter sales of Eylea (aflibercept) in the United States increased 14% to (Read more...)
Uncategorized